We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Ultragenyx Appoints Sunil Agarwal as Chief Medical Officer and Senior Vice President

Ultragenyx Appoints Sunil Agarwal as Chief Medical Officer and Senior Vice President

Ultragenyx Appoints Sunil Agarwal as Chief Medical Officer and Senior Vice President

Ultragenyx Appoints Sunil Agarwal as Chief Medical Officer and Senior Vice President

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Ultragenyx Appoints Sunil Agarwal as Chief Medical Officer and Senior Vice President"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Ultragenyx Pharmaceutical Inc. has announced that it has appointed Sunil Agarwal, M.D. as its Chief Medical Officer and Senior Vice President, effective August 25, 2014. In this role, Dr. Agarwal will provide strategic leadership and direction to Clinical Operations, Clinical Development, Regulatory Affairs, Biometrics, Pharmacovigilance, and Non-Clinical Research. He will report to Emil D. Kakkis, M.D., Ph.D., Ultragenyx’s CEO, and will serve on the Senior Management Team.

Dr. Agarwal most recently served as Senior Vice President and Global Head of Clinical Development for Immunology and Infectious Diseases, Metabolism, Neuroscience, and Ophthalmology at Genentech. During his tenure at Genentech, Dr. Agarwal also held the positions of Senior Vice President for Immunology and Infectious Diseases and Vice President for Rheumatology.

Prior to the integration with Roche, he served as Vice President of Genentech Drug Safety and held positions of increasing responsibility in Genentech's Immunology clinical organization. Prior to joining Genentech, Dr. Agarwal was at MedImmune, Guilford Pharmaceuticals, and Kosan Biosciences. Over his industry career, Dr. Agarwal has successfully led multiple drug approvals across various therapeutics areas including orphan indications.

Dr. Agarwal obtained his bachelor of science in Neuro-Biology at Cornell University and then earned his medical degree from Tufts University School of Medicine. He completed his residency at Children's National Medical Center, Washington, D.C. and subsequently joined the faculty at George Washington University School of Medicine as an Assistant Clinical Professor of Pediatrics.

“On behalf of the Board of Directors and the Executive team, I am pleased to announce the addition of Dr. Agarwal to the Ultragenyx team. With over 15 years in the biotechnology industry in progressive leadership roles, his clinical development expertise and proven track record make him an excellent fit to achieve our mission of developing novel treatments for rare and ultra-rare diseases,” said Dr. Kakkis. “Dr. Agarwal’s appointment reflects the strength of our clinical stage pipeline and he will join our senior team to help lead the execution of our development programs.”

“I am excited about joining the leadership team at Ultragenyx to support the continued progress and growth of the company’s product pipeline”, commented Dr. Agarwal. “To develop novel therapies for these patients who have no approved treatments and to help push the science forward in these rare genetic diseases is something I am thrilled to be a part of.”

Dr. Agarwal will join the senior medical team at Ultragenyx which includes Dr. Kakkis and Dr. Javier San Martin, Vice President, Clinical Development, a key leader for the KRN23 development program for X-linked hypophosphatemia (XLH).

Prior to Ultragenyx, Dr. San Martin worked at Amgen as the Global Development Leader for the sclerostin antibody program and Prolia (denosumab) and at Eli Lilly as medical advisor on the Forteo (teriparatide) Product Team.